Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA Exploring new territories of oncology and immunology in search of therapeutic approaches able to save lives Very serious about incurable diseases Breaking the impasse with “sole-in-class" drug candidates Latest news Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022 Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer February 8, 2022 Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021 See all press releases Upcoming events See all upcoming events
Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021
